List view / Grid view
Neuroscientists are increasingly viewing disorders of the brain through the lens of the underlying molecular mechanisms as sometimes illuminated by genetic variants, rather than classifying disorders based solely on the clinical symptoms. The next step in the evolution of antiseizure medication will likely come from studying these molecular determinants of…
The discovery that CNTN4 and APP have a co-dependent relationship has wider implications for neurodevelopmental disorder understanding.
Researchers showed that ESI1, or similar compounds, may help to slow or even reverse cognitive losses that can occur during aging.
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
Adult anxious behaviour in offspring may be related to the early life proinflammatory state caused by the absence of elevated XCL1.
In this Q&A, we speak to Dr Emma Murphy, Head of Biology at the Alzheimer’s Research UK Oxford Drug Discovery Institute. Among her many insights, she discusses how the challenges in developing reproducible assays can be addressed, as well as strategies used to translate promising findings into clinically relevant tools…
Researchers find the mechanism which may underly the onset and progression of age-related neurodegenerative diseases.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
Download this free report to explore the future of neuroscience and current developments in drug discovery. It features interviews with experts discussing challenges and historical influences in the field, the role of neuroscientists in addressing environmental issues, and personal journeys in neuroscience.
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.
Researchers have gained a deeper understanding of the neural biology of obesity, which could offer potential drug targets.
Researchers have presented new findings that offer potential pathways to arrest critical steps toward the accumulation of mutant tau.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
New findings about how long genes become less active with age could impact treatments for neurodegeneration, among other conditions.
